| Excerpt | Reference |
|---|
| "Dyslipidemia is common in patients with HIV infection." | ( Cade, WT; DeMoss, A; Fontana, L; Klein, S; Laciny, E; Patterson, BW; Powderly, WG; Reeds, DN; Yarasheski, KE, 2006) |
| "The role of dyslipidemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidemic patients is an extremely important task in cardiovascular prevention." | ( Ilyés, I; Jancsó, Z; Simay, A; Varga, Z, 2005) |
| "Atherogenic dyslipidemia is one of the major components of the metabolic syndrome, a complex cluster of several risk factors within a single patient that according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III includes at least 3 of the following: large waist circumference, elevated triglyceride levels, low levels of high-density lipoprotein cholesterol (HDL-C), hypertension, and elevated fasting glucose levels, which are directly related to the incidence of coronary heart disease." | ( Vinik, AI, 2005) |
| "Dyslipidemia is almost always present when proteinuria is above 3 gr/24 hours." | ( Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V, 2006) |
| "The incidence of dyslipidemia is rising worldwide." | ( Harangi, M; Paragh, G, 2006) |
| "Dyslipidemia is a feature of polycystic ovary syndrome (PCOS), but its pathogenesis remains controversial." | ( Apridonidze, T; Dunaif, A; Essah, PA; Legro, RS; Sam, S, 2006) |
| "Postprandial dyslipidemia is recognized as an important complication of insulin-resistant states, and recent evidence implicates intestinal lipoprotein overproduction as a causative factor." | ( Adeli, K; Federico, LM; Naples, M; Taylor, D, 2006) |
| "Dyslipidemia is a highly heterogeneous group of disorders strongly influenced by both genetic and environmental factors." | ( Armani, A; Toth, PP, 2006) |
| "Since dyslipidemia is common in diabetes and is associated with increased cardiovascular risk, we tested the hypothesis that Thr-54 is associated with increased cardiovascular risk in patients with diabetes." | ( Bloomfield, H; Brousseau, ME; Collins, D; Georgopoulos, A; O'Connor, JJ; Ordovas, JM; Robins, SJ; Schaefer, EJ, 2007) |
| "Dyslipidemia is not routinely evaluated in emergency department (ED) patients." | ( Blomkalns, AL; Eady, CE; Gibler, WB; Lindsell, CJ; O'Connell, EM, 2006) |
| "Asian Indian dyslipidemia is characterized by: borderline high low-density lipoprotein (LDL) cholesterol and apolipoprotein (apo) B; high triglycerides, low high-density lipoprotein (HDL) cholesterol and apoA1; and high lipoprotein(a) (lp[a])." | ( Gupta, R; Hira, HS; Kumar, N; Mohan, B; Panwar, RB; Sharma, DR; Sharma, M; Sharma, SK; Singh, V, 2006) |
| "Dyslipidemia is a common metabolic complication among HIV-infected patients who receive protease inhibitor (PI)-based antiretroviral therapy (ART)." | ( Hiransuthikul, N; Hiransuthikul, P; Kanasook, Y, 2007) |
| "Also, dyslipidemia is currently interpreted as the result of increased flux of free fatty acids to the liver with ensuing misbalance of lipoprotein synthesis and removal." | ( Lo Sasso, G; Moschetta, A; Palasciano, G; Petruzzelli, M; Portincasa, P, 2007) |
| "Dyslipidemia is one of the primary causes of atherosclerosis and effective interventions to correct dyslipidemia should form an integral component of any strategy aimed at preventing cardiovascular disease." | ( Athyros, VG; Tziomalos, K, 2006) |
| "Proteinuria and dyslipidemia are nonimmune risk factors implicated in the deterioration of kidney function and associated with an increased risk of accelerated atherogenesis." | ( Bayés, B; Blanco, S; Bonet, J; Lauzurica, R; Navarro-Muñoz, M; Romero, R, 2007) |
| "Dyslipidemia is a common problem among heart transplant (HT) recipients; it is a frequent risk factor in these patients that is exacerbated by immunosuppressive drugs." | ( Agüero, J; Almenar, L; Izquierdo, M; Martínez-Dolz, L; Moro, J; Ortiz, V; Salvador, A; Sánchez-Lazaro, I, 2007) |
| "Dyslipidemia is a pathological alteration of serum lipid levels." | ( Popescu, L; Rau, O; Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H, 2008) |
| "Dyslipidemia is common in the Iraqi population, and this was identified at different recommendation criteria." | ( Chilmeran, SK; Mula-Abed, WA, 2007) |
| "Dyslipidemia is a significant risk factor for the development of atherosclerotic disease and of chronic allograft rejection." | ( Boccalini, F; Castagneto, M; Citterio, F; Fioravanti, G; Navarra, P; Pozzetto, U, 2008) |
| "Dyslipidemia is a primary risk factor for developing coronary heart disease and stroke, frequent causes of morbidity and mortality in Colombia and the world." | ( Machado, JE; Mesa, G; Moncada, JC, 2008) |
| "Dyslipidemia is a well recognized side effect of sirolimus therapy, which may have an impact on patient survival and post-transplant cardiac morbidity and mortality." | ( Al-Jedai, AH; Hakeam, HA; Hamawi, K; Raza, SM, 2008) |
| "Managing dyslipidemia is an important part of the primary and secondary prevention of coronary heart disease." | ( Nambi, V; Polsani, VR; Virani, SS, 2008) |
| "Treatment of dyslipidemia is important for the primary and secondary prevention of cardiovascular events." | ( Miura, S; Saku, K, 2008) |
| "Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol and a concomitant increase in atherogenic small dense low-density lipoproteins." | ( Berneis, K; Christ, ER; Rini, GB; Rizzo, M; Spinas, GA, 2008) |
| "Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and anti-atherogenic lipoproteins." | ( Farnier, M, 2008) |
| "Dyslipidemia is a major risk factor in the initiation and progression of cardiovascular diseases such as atherosclerosis." | ( Arora, A; Khan, BV; Pandian, A; Sperling, LS, 2008) |
| "Dyslipidemia is central to the process of atherosclerosis." | ( Farmer, JA, 2009) |
| "Dyslipidemia is common in women with polycystic ovary syndrome (PCOS) but its prevalence in different PCOS phenotypes is still largely unknown." | ( Berneis, K; Carmina, E; Di Fede, G; Hersberger, M; Pepe, I; Rini, GB; Rizzo, M; Spinas, GA, 2009) |
| "Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition." | ( Bangalore, S; Devabhaktuni, M, 2009) |
| "Midgestation dyslipidemia is associated with mild but not severe preeclampsia." | ( Baker, AM; Boggess, K; Haeri, S; Klein, RL; Moss, KL, 2009) |
| "Dyslipidemia is a well-established condition proved to accelerate the progression of chronic kidney disease leading to tubulo-interstitial injury." | ( Boffoli, D; Calabresi, L; Capitanio, N; Cirillo, P; D'Aprile, A; Gesualdo, L; Gomaraschi, M; Montemurno, E; Piccoli, C; Quarato, G; Ripoli, M; Scrima, R, 2011) |
| "Dyslipidemia is a metabolic disorder that constitutes a major risk factor for cardiovascular diseases and stroke and is often associated with diabetes mellitus and atherosclerosis." | ( Baldelli, F; Cipriani, S; Fiorucci, S; Mencarelli, A, 2010) |
| "Dyslipidemia is a well established risk factor for cardiovascular disease and is estimated to account for more than half of the global cases of coronary artery disease." | ( Alpert, JS; Rough, SJ; Shanmugasundaram, M, 2010) |
| "Dyslipidemia is commonly observed in polycystic ovary syndrome (PCOS) patients." | ( Amita, M; Hara, S; Igarashi, H; Kurachi, H; Takahashi, T, 2010) |
| "Dyslipidemia is common among HIV-infected patients receiving antiretroviral therapy." | ( Fichtenbaum, CJ; Samineni, D, 2010) |
| "Dyslipidemia is a risk factor for incident type 2 diabetes; however, no study has specifically assessed the lipid ratios (i." | ( Azizi, F; Hadaegh, F; Hatami, M; Saadat, N; Sarbakhsh, P; Tohidi, M, 2010) |
| "Hyper- and dyslipidemia are risk factors for cardiovascular disease, the primary cause of death in industrialized countries." | ( Beck, V; Jungbauer, A; Mueller, M, 2011) |
| "Dyslipidemia is an important modifiable risk factor." | ( Campbell, J; Mohiuddin, SM, 2010) |
| "Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced levels of high-density lipoproteins (HDL) in the circulation." | ( Balakumar, P; Mahadevan, N; Rohilla, A, 2011) |
| "Dyslipidemia is one of the main risk factors leading to atherosclerotic cardiovascular disease (CVD)." | ( Manolopoulos, VG; Ragia, G; Tavridou, A, 2011) |
| "dyslipidemia is common and is often treated with 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins)." | ( Crane, HM; Crane, PK; Harrington, RD; Kitahata, MM; Knopp, RH; Kosel, BW; Mugavero, MJ; Saag, MS; Singh, S; Willig, JH, 2011) |
| "Type 1 diabetes and dyslipidemia are known risk factors for cardiovascular disease (CVD), but the relationship between lipid levels in youth with type 1 diabetes and future CVD remains unknown." | ( Kaufman, FR; Mittelman, SD; Reh, CM; Shah, AC; Wee, CP; Wood, JR, 2011) |
| "Dyslipidemia is an important risk factor for CVD and effective treatment significantly reduces cardiovascular risk." | ( Cardoso, SM; da Silva, PM, 2011) |
| "Dyslipidemia is a common complication of chronic kidney disease (CKD) and contributes to cardiovascular morbidity and mortality of CKD patients." | ( Abe, S; Ikeda, H; Inoue, T; Kikuchi, M; Kishi, T; Miyazono, M; Nakamura, T; Node, K; Sanai, T; Taguchi, I; Toyoda, S, 2011) |
| "Dyslipidemia is an important risk factor for cardiovascular complications in persons with diabetes." | ( Lyons, TJ; Wu, M, 2011) |
| "Dyslipidemia is closely related to erectile dysfunction (ED)." | ( Ho, AL; Lee, CP; Lee, VW; Ng, CF, 2011) |
| "Dyslipidemia is frequently found in association with obesity." | ( Repas, T, 2011) |
| "Atherogenic dyslipidemia is highly associated with coronary heart disease and is characterized by elevated triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C), and elevated low-density lipoprotein cholesterol (LDL-C)." | ( Ballantyne, CM; Belmont, J; Brautbar, A; Covarrubias, D; Jones, PH; Lara-Garduno, F; Leal, SM; Virani, SS, 2011) |
| "Atherogenic dyslipidemia is characterised by high levels of triglycerides, low levels of high-density lipoprotein-cholesterol (HDL-C), and moderate to marked elevations in low-density lipoprotein-cholesterol (LDL-C) concentrations; such dyslipidemia is further characterised by high apolipoprotein B (apoB): apolipoprotein A1 (apoA1) ratios." | ( Chapman, MJ, 2011) |
| "Dyslipidemia is frequent at 1 year after transplantation." | ( Felipe, CR; Mandia-Sampaio, EL; Medina-Pestana, JO; Park, SI; Spinelli, GA; Tedesco-Silva, H, 2011) |
| "Dyslipidemia is a relatively common problem observed in clinical practice, seen both in instances when evaluating patients with subjective problems as well as among those coming to take a regular preventive exams." | ( Jelena, S; Talirevic, E, 2012) |
| "Dyslipidemia is a leading risk factor for cardiovascular disease and is also a common feature of obesity." | ( Amini, M; Ferns, GA; Ghayour-Mobarhan, M; Iranshahi, M; Khojasteh, R; Mohammadi, A; Sahebkar, A, 2013) |
| "Dyslipidemia is more common in generalized than in localized/disseminated disease, and the annular lesion morphology is associated with hypercholesterolemia and DLP." | ( Jung, HY; Kokkotou, E; Kroumpouzos, G; Robinson-Bostom, L; Wu, W, 2012) |
| "HIV-dyslipidemia is a common problem with extensive use of combination antiretroviral therapy (CART), and is associated with an increase in incidence of cardiovascular disease (CVD), resulting in hospital admission and surgery throughout the western healthcare systems." | ( Ahmed, MH; Al-Atta, A; Hamad, MA, 2012) |
| "The prevalence of dyslipidemia is high in Chongqing enterprises and institutions." | ( Gao, Y; Tian, KC; Yang, YH; Zhong, XN, 2012) |
| "Although diabetic dyslipidemia is characterized by hypertriglyceridemia, low HDL-cholesterol, and small dense LDL particles, the main determinant of the role of dyslipidemia in the prognosis of diabetics is LDL cholesterol." | ( Barrios, V; Escobar, C, 2013) |
| "Dyslipidemia is a major coronary heart disease (CHD) risk factor." | ( Sahebkar, A, 2013) |
| "Dyslipidemia is one the most well-established risk factors for cardiovascular disease development." | ( Dixon, J; Eikelis, N; Esler, M; Head, G; Hering, D; Lambert, E; Lambert, G; Sari, CI; Schlaich, M; Straznicky, N, 2013) |
| "Dyslipidemia is a major risk factor for cardiovascular (CV) disease - the primary cause of death, worldwide." | ( Fruchart, JC, 2013) |
| "Dyslipidemia is highly common in Malaysian HIV subjects receiving ARV medication." | ( Choong, CL; Hejazi, N; Rajikan, R; Sahar, S, 2013) |
| "Dyslipidemia is a clinical condition with a relatively high prevalence in the population and has been associated with an increased thrombotic risk." | ( Ene, G; García Raso, A; Llamas Sillero, MP; Mata, R; Miranda, C; Vidal, R, 2014) |
| "Dyslipidemia is highly prevalent in primary health care users in Portugal." | ( Belo, A; Cortez-Dias, N; Fiúza, M; Robalo Martins, S, 2013) |
| "Dysglycemia and dyslipidemia are important metabolic complications of organ transplantation." | ( Ahn, CW; Cha, BS; Cho, Y; Choe, EY; Huh, KH; Kang, ES; Kim, MS; Kim, YS; Kwon, O; Lee, HC; Wang, HJ, 2014) |
| "Dyslipidemia is a major risk factor for the development of cardiovascular diseases and statins are the common drugs used to correct dyslipidemia." | ( Abraham, SJ; Ganesh, JS; Iwasaki, M; Jayakrishnan, GA; Preethy, S; Rao, YY; Ravikumar, R, 2014) |
| "Dyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs)." | ( Akhlaghi, F; Asberg, A; Ghareeb, M; Granseth, T; Holdaas, H; Midtvedt, K; Molden, E; Reier-Nilsen, M; Robertsen, I; Vethe, NT, 2014) |
| "Dyslipidemia is a risk factor for not only cardiovascular diseases (CVD), but also chronic kidney disease (CKD)." | ( Iwasaka, T; Jo, F; Kubo, R; Kusabe, M; Morimoto, S; Morita, T; Nakahigashi, M; Nakano, C; Okuno, Y; Seo, M; Shiojima, I; Someya, K; Takahashi, N; Toyoda, N; Ueda, H, 2014) |
| "Dyslipidemia is manageable via statin treatment, while the anti-diabetic drug metformin would prevent hyperglycemia." | ( De Loof, H; De Meyer, GRY; Martinet, W, 2014) |
| "Dyslipidemia is a common feature in patients with PM that is characterized by a decrease in HDL-C and an increase in TG, suggesting a high risk of atherosclerosis." | ( Cai, L; Cai, Y; Chen, X; Deng, J; Hu, Y; Wang, H, 2014) |
| "Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus (DM)." | ( Divya, BT; Mini, S, 2014) |
| "Dyslipidemia is a major risk factor for premature atherosclerosis and CVD." | ( Chapman, MJ; Kontush, A; Rached, FH, 2014) |
| "The prevalence of dyslipidemia is very high in India, which calls for urgent lifestyle intervention strategies to prevent and manage this important cardiovascular risk factor." | ( Anjana, RM; Bhansali, A; Das, AK; Deepa, M; Dhandania, VK; Joshi, PP; Joshi, SR; Kaur, T; Madhu, SV; Mohan, V; Nirmal, E; Pradeepa, R; Rao, PV; Shukla, DK; Subashini, R; Unnikrishnan, R, 2014) |
| "The incidence of dyslipidemia is high and the influencing factors are common among the elderly." | ( Chen, W; Chen, Z; Hu, J; Li, D; Liu, J; Yang, F, 2014) |
| "Post-transplant dyslipidemia is exacerbated by mammalian target of rapamycin (mTOR) inhibitors." | ( Holdaas, H; Potena, L; Saliba, F, 2015) |
| "Dyslipidemia is a major public health problem, and therefore, it is important to develop dietary strategies to diminish the prevalence of this disorder." | ( Castellanos-Jankiewicz, A; del Bosque-Plata, L; Guevara-Cruz, M; Tejero, ME; Torres, N; Tovar, AR, 2014) |
| "Dyslipidemia is a major public health problem, and therefore, it is important to develop dietary strategies to diminish the prevalence of this disorder." | ( Castellanos-Jankiewicz, A; del Bosque-Plata, L; Guevara-Cruz, M; Tejero, ME; Torres, N; Tovar, AR, 2014) |
| "Dyslipidemia is associated with aggressive periodontitis, a condition characterized by the rapid destruction of the periodontium." | ( Chen, Z; Feng, X; Gao, H; Hou, J; Lu, R; Meng, H; Shi, D; Tian, Y; Wang, X; Xu, L; Zhang, L, 2015) |
| "Dyslipidemia is one of the classical risk factors for developing CVD." | ( Bousoula, E; Kolovou, G; Kolovou, V; Perrea, D, 2015) |
| "Diabetic dyslipidemia is characterized by the so-called atherogenic lipid triad, consisting of an increase in small dense low density lipoprotein particles and in triglyceride-rich lipoproteins, and a decrease in high-density lipoprotein cholesterol, with an increase in non-HDL cholesterol." | ( Farnier, M, 2015) |
| "Diabetes and dyslipidemia are commonly associated modifiable risk factors for cardiovascular diseases." | ( Joshi, SR, 2015) |
| "Dyslipidemia is commonly seen in patients with type 2 diabetes mellitus (T2DM)." | ( Bao, Y; Deng, Z; Jia, W; Li, H; Lu, J; Mo, Y; Peng, Y; Zhang, X; Zhou, J, 2015) |
| "Dyslipidemia is highly prevalent in women, particularly after the menopause." | ( Cífková, R; Krajčoviechová, A, 2015) |
| "Dyslipidemia is an established risk factor for ischemic heart disease." | ( Asgary, S; Goli-Malekabadi, N; Sahebkar, A, 2015) |
| "Dyslipidemia is increased fasting level of total cholesterol (TC), LDL cholesterol (LDL-C), and triglycerides (TG), along with decreased levels of HDL cholesterol (HDL-C)." | ( Abdollahi, M; Bahadar, H; Maqbool, F; Niaz, K; Rahimifard, M; Safavi, M, 2015) |
| "Dyslipidemia is a key factor determining the development of both myocardial infarction (MI) and its subsequent complications." | ( Barbarash, O; Belik, E; Dyleva, Y; Gruzdeva, O; Karetnikova, V; Uchasova, E, 2015) |
| "Dyslipidemia is a strong risk factor for cardiovascular disease among patients with type 2 diabetes (T2D)." | ( Hong, J; Kong, X; Xing, X; Yang, W; Zhang, B; Zhang, X; Zhao, Q, 2015) |
| "Dyslipidemia is a risk factor for cardiovascular disease, which is a major contributor to mortality in Canada." | ( , 2014) |
| "Dyslipidemia is a well-established risk factor for cardiovascular disease." | ( Dai, SX; Huang, JF; Li, WX; Lv, WW; Pan, ML, 2015) |
| "Dyslipidemia is a risk factor for intimal hyperplasia (IH)." | ( Desai, P; Gahtan, V; Maier, KG; Siddiqui, SA; Stein, JJ, 2015) |
| "Dyslipidemia is a treatable risk factor for cardiovascular disease." | ( Lavie, CJ; Parto, P; Sui, X; Swift, D, 2015) |
| "This type of dyslipidemia is frequently observed in CKD patients and is a modifiable risk factor for CVD." | ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| "Dyslipidemia is a major independent and reversible risk factor for these diseases: it is estimated that a reduction of 1 mmol/l (38 mg/dl) of LDL cholesterol is associated with a risk of developing a cardiovascular complication reduced by 25%, a reduction potentially achieved by life-style improvement associated to adequate dietary supplementation with bioactive substances." | ( Cicero, AF; Colletti, A, 2016) |
| "Dyslipidemia is a "primary or secondary pathological changes in serum lipids"." | ( Ba, SA; Diao, M; Kane, A; Mbaye, A; Ngaide, AA; Sarr, SA; Thiombiano, LP, 2016) |
| "The prevalence of dyslipidemia is very high in our regions." | ( Ba, SA; Diao, M; Kane, A; Mbaye, A; Ngaide, AA; Sarr, SA; Thiombiano, LP, 2016) |
| "Usually this dyslipidemia is improved by a good control of hyperglycemia." | ( Oikawa, S, 2015) |
| "Dyslipidemia is a risk factor for the pathogenesis of Alzheimer's disease." | ( Wan, Q; Zhao, L; Zhao, Q; Zhao, Y; Zhou, Y, 2016) |
| "Dyslipidemia is an important factor in MetS and is related to atrial fibrillation (AF)." | ( Chen, CH; Chu, CS; Hsiao, YL; Ke, LY; Lai, WT; Lee, HC; Lin, HT; Sheu, SH; Shin, SJ; Wei, C; Wu, BN, 2016) |
| "Dyslipidemia is one of the most common adverse effects in schizophrenia patients treated with antipsychotics." | ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| "Prevalence of dyslipidemia is high in obese children, and hypertriglyceridemia is in the foreground." | ( Demirel, F; Elmaoğulları, S; Karaca Kara, F; Tepe, D; Uçaktürk, SA, 2015) |
| "Dyslipidemia is more prevalent among unfit/overweight-obese children and adolescents compared with fit/underweight-normal weight boys (PR: 1." | ( Burgos, MS; da Silva, PT; da Silva, R; de Mello, ED; Pasa, L; Renner, JD; Reuter, CP; Valim, AR, 2016) |
| "The prevalence of dyslipidemia is directly related to both obesity and lower levels of cardiorespiratory fitness." | ( Burgos, MS; da Silva, PT; da Silva, R; de Mello, ED; Pasa, L; Renner, JD; Reuter, CP; Valim, AR, 2016) |
| "Advanced dyslipidemia is described to induce RAS activation in the vasculature." | ( Côco, H; de Oliveira, AM; Franco, JJ; Gomes, MS; Hipólito, UV; Marchi, KC; Pereira, PC; Pernomian, L; Tirapelli, CR; Uyemura, SA, 2016) |
| "Dyslipidemia is commonly seen in human immunodeficiency virus (HIV) infected patients." | ( Ding, H; Geng, W; Guo, X; Jiang, Y; Kang, J; Li, X; Liu, J; Shang, H; Wang, Q; Xu, J, 2016) |
| "Atherogenic dyslipidemia is initiated in an early stage of impaired glucose metabolism, when early intervention might be required." | ( Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS, 2016) |
| "Dyslipidemia is a common pathology throughout the industrialized world, and HMG-CoA reductase inhibitors (statins) are often administered to treat elevated lipid levels." | ( Gendle, MH, 2016) |
| "Dyslipidemia is a risk factor for cardiovascular disease, with elevated low-density lipoprotein cholesterol (LDL-C) and decreased high-density lipoprotein cholesterol (HDL-C) recognized as risk factors for acute coronary events." | ( Dodani, S; Donnelly, JP; Guirgis, FW; Howard, G; Levitan, EB; Safford, MM; Wang, HE, 2016) |
| "Dyslipidemia is a risk factor for nonalcoholic fatty liver disease (NAFLD)." | ( Mo, Z; Peng, K; Tian, G, 2017) |
| "Dyslipidemia is common and one of the therapeutic targets in patients with ACS." | ( Fujisue, K; Tsujita, K, 2017) |
| "Atherogenic dyslipidemia is an important modifiable risk factor for cardiovascular disease among patients of type 2 diabetes mellitus." | ( Acharya, S; Kafle, R; Khadka, D; Pokharel, DR; Sapkota, RM; Sigdel, M; Sigdel, T; Yadav, NK, 2017) |
| "Atherogenic dyslipidemia is associated mainly with male gender, poor glycemic control and hypertension." | ( Acharya, S; Kafle, R; Khadka, D; Pokharel, DR; Sapkota, RM; Sigdel, M; Sigdel, T; Yadav, NK, 2017) |
| "Obesity and dyslipidemia are the most common comorbidities among persons with DM and HTN alone and comorbid DM and HTN." | ( Jain, S; Jeet, G; Thakur, JS; Tripathy, JP, 2017) |
| "Dyslipidemias are defined as changes in lipid metabolism that have abnormal concentrations of lipids or lipoproteins in the bloodstream." | ( Barros, AS; Carvalho, HO; Carvalho, JCT; da Cunha, EL; E Souza, BSF; Ferreira, IM; Taglialegna, T, 2017) |
| "Dyslipidemia is a major complication of antiretroviral treatment." | ( Boydak, B; Gökengin, D; Tuncel Başoğlu, M; Uysal, S, 2017) |
| "Dyslipidemia is reported in 27 - 43% of children and adolescents with overweight/obesity and tracks into adulthood, increasing the risk of cardiovascular morbidity." | ( Bratholm, PS; Bøjsøe, C; Fonvig, CE; Hansen, T; Holm, JC; Lausten-Thomsen, U; Nielsen, TRH; Pedersen, L; Pedersen, O, 2017) |
| "Dyslipidemia is caused by disturbances in lipid metabolism that lead to chronic elevations of serum lipids, especially low-density lipoprotein (LDL)-cholesterol and triglycerides, increasing the risk of metabolic syndrome, obesity, diabetes, atherogenic processes, and cardiovascular diseases." | ( Barros, ASA; Carvalho, HO; Carvalho, JCT; da Cunha, EL; Faria E Souza, BS; Ferreira, IM; Keita, H; Navarrete, A; Taglialegna, T, 2017) |
| "Lipodistrophy and dyslipidemia are the main causes of long-term toxicities." | ( Cicalini, S; D'Abbraccio, M; d'Ettorre, G; Di Biagio, A; Maggi, P; Martinelli, C; Nunnari, G; Rusconi, S; Sighinolfi, L; Spagnuolo, V; Squillace, N, 2017) |
| "Dyslipidemia is an increasing epidemic in China, characterized by a rising trend of LDL cholesterol." | ( Bi, Y; Gu, T; Sun, J; Wang, J; Zhou, W; Zhu, D, 2018) |
| "Obesity and dyslipidemia is the two facet of metabolic syndrome, which needs further attention." | ( Babu, MH; Gaikwad, AN; Gupta, A; Kumar, D; Puri, S; Rajan, S; Reddy, MS; Shankar, K; Srivastava, A; Varshney, S, 2018) |
| "The problem of dyslipidemia is high in patients with diabetes mellitus." | ( Abebe, M; Abebe, SM; Alemu, A; Baynes, HW; Biadgo, B; Yesuf, M, 2017) |
| "Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk." | ( Al-Rasadi, K; Katsiki, N; Mikhailidis, DP; Pirro, M; Reiner, Ž; Sahebkar, A; Tedeschi Reiner, E, 2018) |
| "Dyslipidemia is a major risk factor for a number of chronic diseases, including diabetes and cardiovascular diseases." | ( Abd Elhalem, SS; Badr, G; El-Shinnawy, NA; Haggag, NZ, 2018) |
| "Dyslipidemia is a major risk factor for cardiovascular events." | ( Alexander, JH; Alings, M; Erol, C; Goto, S; Granger, CB; Halvorsen, S; Hanna, M; Held, C; Hijazi, Z; Huber, K; Lindbäck, J; Lopes, RD; Pol, T; Ruzyllo, W; Westerbergh, J, 2018) |
| "Dyslipidemia is the key precursor of atherosclerotic cardiovascular disease." | ( Abdullah, N; Aminudin, N; Seng, CK, 2017) |
| "Dyslipidemia is the main risk factor for developing cardiovascular disease." | ( Fazelian, S; Heshmati, J; Khorshidi, M; Namazi, N; Sepidarkish, M; Shidfar, F; Shokri, F; Yavari, M, 2019) |
| "Dyslipidemia is the leading cause of atherosclerotic cardiovascular diseases (ASCVD) in T2D patients." | ( Chen, Y; Deng, H; Deng, X; Liu, HY; Liu, SM; Qin, S; Yuan, E, 2018) |
| "Hypertension and dyslipidemia are 2 risk factors of cardiovascular disease that often present simultaneously." | ( Bae, JH; Baek, SH; Cho, J; Choi, YJ; Doh, JH; Han, JK; Han, KH; Hong, KS; Hyon, MS; Ihm, SH; Jeong, JO; Kim, H; Kim, HS; Kim, MH; Kim, SH; Kim, SJ; Lee, BK; Oh, GC; Rhee, MY; Rhew, JY; Shin, ES; Sung, JH; Yoo, BS, 2018) |
| "Patients with dyslipidemia are often treated with statins to reduce lipids and hence cardiovascular risk, but treatment response is variable, partly due to genetic factors." | ( Alía-Ramos, P; Candás-Estébanez, B; Cano-Corres, R; Fanlo-Maresma, M; Padró-Miquel, A; Pintó, X, 2018) |
| "Thus, dyslipidemia is influenced by APOA1, ABCA1, LCAT, environmental factors, and their interactions." | ( Ding, Y; Guo, H; Guo, S; He, J; Hu, Y; Li, S; Li, Y; Liu, J; Ma, J; Ma, R; Mu, L; Niu, Q; Wang, H; Wang, X; Yan, Y; Zhang, J; Zhang, M, 2018) |
| "Dyslipidemia is an important cardiovascular risk factor in steroid-resistant nephrotic syndrome (SRNS)." | ( Bagga, A; Hari, P; Hari, S; Khandelwal, P; Lakshmy, R; Satpathy, A; Sinha, A; Thergaonkar, R, 2018) |
| "Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment-which represents the cornerstone of therapy-a relevant practical uncertainty regards the use of fibrate derivatives." | ( Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Romano, S; Santoro, F; Tarantino, N, 2018) |
| "Hypertension and dyslipidemia are major risk factors for cardiovascular disease (CVD)." | ( Liu, Y; Shao, Y; Tao, J; Zhang, J, 2018) |
| "Dyslipidemia is a major risk factor in triggering cardiovascular events, which can lead to the death of millions of people around the world." | ( Costa, LR; Costa, PS; Fortes, PM; Marques, SM; Naghettini, AV; Viana, KA, 2018) |
| "Dyslipidemia is a major health problem that may lead to cardiovascular diseases (CVDs)." | ( Al-Okbi, SY; Elbakry, HFH; Fouda, KA; Hassan, ME; Hussein, AMS; Mahmoud, KF, 2018) |
| "Dyslipidemia is a major risk factor for the development of cardiovascular disease." | ( Chae, SM; Choi, HD, 2018) |
| "Diabetic dyslipidemia is associated with insulin resistance, high plasma triglyceride levels, low HDL-cholesterol concentration and elevated small dense LDL-cholesterol particles." | ( Balakumar, P; Mahadevan, N; Sambathkumar, R, 2019) |
| "Dyslipidemia is one of the most frequently implicated risk factors for development of atherosclerosis." | ( Goel, A; Gupta, S; Prabhu, S; Prasad, A; Subramanian, D; Upadya, H, 2019) |
| "Dyslipidemia is known as a common clinical disease that affects the health of millions of people around the world." | ( Chen, J; Hu, X; Huang, C; Li, P; Lin, D; Wu, A; Xue, X; Yang, H; Yang, Z; Ye, C, 2019) |
| "Dyslipidemias is associated with GBP formation." | ( Fei, L; Liwei, L; Xuesong, B; Yamin, Z; Yue, H; Zhen, Z, 2020) |
| "The Chinese dyslipidemia is characterized by high triglycerides and low HDL-C and occurs in young and middle-aged individuals." | ( Ding, X; Fang, Y; Jiang, X; Wang, L; Xu, L; Xue, N; Zhang, X, 2019) |
| "Dyslipidemia is a common disorder in systemic lupus erythematosus (SLE) patients." | ( Chen, T; Cheng, GY; Jiang, YM; Liu, D; Shang, J; Tao, CY; Xiao, J; Yu, D; Zhao, ZZ, 2019) |
| "Dyslipidemia is an important modifiable risk factor for cardiovascular disease." | ( Bosl, W; Hatthachote, P; Narindrarangkura, P; Rangsin, R, 2019) |
| "Dyslipidemia is prevalent among Thai T2DMpatients and is associated with gender; age; obesity; central obesity; treatment at a primary care unit; and a history of unknown stroke, coronary revascularization, diabetic nephropathy, and renal insufficiency." | ( Bosl, W; Hatthachote, P; Narindrarangkura, P; Rangsin, R, 2019) |
| "Dyslipidemia is associated with abnormal serum lipid profiles viz." | ( Alsayari, A; Balakumar, P; Dhanaraj, SA; Mahadevan, N; Muhsinah, AB; Sambathkumar, R; Venkateswaramurthy, N, 2019) |
| "Dyslipidemia is a global health problem and a high risk factor for atherosclerosis, which can lead to serious cardiovascular disease (CVD)." | ( Dong, H; Fang, K; Gong, J; Hu, M; Huang, W; Lu, F; Qin, X; Qiu, X; Wang, D; Yang, X; Yuan, F, 2019) |
| "Dyslipidemia is a major risk factor for cardiovascular disease, the leading cause of preventable death worldwide." | ( Adamski, J; Artati, A; Breuninger, TA; Grallert, H; Linseisen, J; Meisinger, C; Peters, A; Wawro, N, 2019) |
| "Given that dyslipidemia is a chronic disease requiring life-long control, active interventions are required for patients with poor adherence and persistence." | ( Fujimoto, G; Hayashi, A; Matsui, N; Piao, Y; Tokita, S; Umeda, T, 2019) |
| "Dyslipidemia is a primary, critical risk factor for cardiovascular disease." | ( Kang, HT; Kwon, YJ; Lee, JW, 2019) |
| "Dyslipidemia is a well-established risk factor for cardiovascular diseases." | ( Bejar, C; Fowler, B; Frazer, JK; Fung, KA; Hopkins, R; Lightfoot, S; Malone-Perez, MW; Mussa, H; Rao, CV; Sanghera, DK; Tan, C; Whitby, P, 2019) |
| "Dyslipidemia is a modifiable risk factor that plays a significant role in the development of atherosclerotic cardiovascular disease." | ( Bellone, J; Dixon, D; Gasbarro, N; Marrs, JC; Tran, R; Wiggins, BS, 2020) |
| "Dyslipidemia is a significant risk factor for NAFLD and NASH." | ( Cariño-Cortés, R; Fernández-Martínez, E; Lira-Islas, IG; Pérez-Hernández, E; Pérez-Hernández, N; Soria-Jasso, LE, 2019) |
| "Dyslipidemia is a key risk factor for cardiovascular diseases, which are a major cause of morbidity and mortality worldwide." | ( Ji, X; Liu, B; Lu, C; Shan, M; Shi, S; Tang, D; Wang, Y; Zhang, H; Zhang, L; Zhang, W; Zhang, Y, 2019) |
| "Dyslipidemia is a well-established modifiable cardiovascular risk." | ( Alisente, S; Baila-Rueda, L; Bea, AM; Cenarro, A; Civeira, F; Giné-González, J; Jarauta, E; Lamiquiz-Moneo, I; Marco-Benedí, V; Mateo-Gallego, R; Pérez-Calahorra, S, 2020) |
| "Dyslipidemia is a common and persistent complication in children with CKD and it worsens in proportion to declining GFR, worsening proteinuria, and increasing BMI." | ( Flynn, JT; Furth, SL; Kupferman, JC; Mitsnefes, MM; Pierce, CB; Saland, JM; Warady, BA, 2019) |
| "Dyslipidemia is a leading risk factor for atherosclerotic cardiovascular disease." | ( Baisley, K; Biraro, S; Grosskurth, H; Hughes, P; Kapiga, S; Katende, D; Kavishe, B; Mghamba, J; Mosha, N; Munderi, P; Mutungi, G; Peck, R; Smeeth, L; Vanobberghen, F, 2019) |
| "Dyslipidemias are common among adults in north-western Tanzania and southern Uganda affecting one third of adult population." | ( Baisley, K; Biraro, S; Grosskurth, H; Hughes, P; Kapiga, S; Katende, D; Kavishe, B; Mghamba, J; Mosha, N; Munderi, P; Mutungi, G; Peck, R; Smeeth, L; Vanobberghen, F, 2019) |
| "Type 2 diabetes and dyslipidemia are diseases that collectively increase the risk of patients developing cardiovascular complications." | ( Ando, M; Arima, H; Banno, R; Furukawa, M; Goto, M; Hagiwara, D; Hamada, Y; Ito, Y; Iwama, S; Kobayashi, T; Morishita, Y; Okada, N; Okuji, T; Onoue, T; Seino, Y; Suga, H; Sugiyama, M; Takagi, H; Tsunekawa, T; Wada, E; Yamamori, E, 2020) |
| "Dyslipidemia is more commonly seen in patients with gout, compared to asymptomatic hyperuricemia." | ( Gu, J; Huang, Y; Jiang, Y; Li, X; Liang, J; Ou, J; Song, W; Wei, Q, 2020) |
| "Dyslipidemia is common among the general population, and its prevention is urgently needed particularly for the health of students." | ( He, L; Ru, D; Wen, S; Xue, B; Zhang, Y; Zhou, H, 2020) |
| "Dyslipidemia is highly prevalent and associated with the long-term prognosis of SLE." | ( Chen, Z; Hu, W; Hua, B; Huang, S; Liu, L; Ma, X; Sun, L; Wang, H; Xu, X; Zhang, X, 2020) |
| "Dyslipidemia is a major cause of early coronary heart disease (CHD)." | ( Adelborg, K; Bruun, JM; Bødtker, H; Falk, E; Gunnersen, S; Kanstrup, H; Kulenovic, I; Mortensen, MB, 2020) |
| "Dyslipidemias are a heterogeneous group of metabolic disorders mainly characterized by an increased risk of atherosclerotic cardiovascular disease (ASCVD) or other conditions, such as acute pancreatitis in hypertriglyceridemia." | ( Cremonini, AL; Formisano, E; Maganza, E; Parodi, E; Pasta, A; Piras, S; Pisciotta, L, 2020) |
| "Dyslipidemia is common in patients with chronic kidney disease (CKD), however the relationship between dyslipidemia and mortality in patients with moderate to severe CKD remains controversial." | ( Chang, JM; Chen, SC; Chiu, H; Huang, JC; Lin, MY; Tu, HP; Wu, PY, 2020) |
| "Dyslipidemia is a well-established risk factor for cardiovascular disease." | ( Hamajima, N; Hishida, A; Kadomatsu, Y; Kawai, S; Kubo, Y; Matsunaga, T; Mori, A; Naito, M; Okada, R; Sasakabe, T; Takeuchi, K; Tamura, T; Tsukamoto, M; Wakai, K; Yin, G, 2020) |
| "Hypertension and dyslipidemia are important risk factors for cardiovascular disease." | ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020) |
| "Dyslipidemia is an important risk factor for cardiovascular disease (CVD)." | ( Chae, IH; Cho, BR; Cho, HC; Chung, CH; Chung, WB; Han, KA; Her, SH; Hwang, BH; Ihm, SH; Jeon, DW; Kang, SH; Kim, HJ; Kim, HS; Kim, JH; Lee, BW; Lee, JB; Lee, JM; Park, SD; Park, TH; Seung, KB; Song, WH; Won, KH; Woo, JT; Yoo, KD; Yu, JM, 2020) |
| "Dyslipidemia is associated with atherosclerosis and cardiovascular disease development, posing serious risks to human health." | ( Chang, D; Deng, Y; Li, G; Su, X, 2020) |
| "Dyslipidemia is a characteristic of maternal obesity and previous studies have demonstrated abnormalities in fatty acid oxidation and storage in term placentas." | ( Bidne, KL; Dodds, ED; Hitt, BD; McCain, AR; Rister, AL; Wood, JR, 2021) |
| "Dyslipidemia is prevalent among patients with hypopituitarism, especially in those with growth hormone (GH) deficiency." | ( da Costa Oliveira, M; Ongaratti, BR; Pereira-Lima, JFS; Rech, CGSL; Rissetti, G; Zeni, D, 2021) |
| "Dyslipidemia is the primary cause of cardiovascular disease, which is a serious human health problem in large parts of the world." | ( Cai, Z; Fredholm, M; Guerin, M; Karlskov-Mortensen, P; Lesnik, P; Lhomme, M; Sahana, G; Zhang, Q, 2020) |
| "The dyslipidemia is associated with altered meibum composition, a key feature of MGD." | ( Brodesser, S; Bullock, T; Burns, AR; Chintapalati, M; Hanlon, S; Osae, EA; Redfern, R; Rumbaut, RE; Smith, CW; Steven, P, 2020) |
| "Dyslipidemia is correlated with a series of health problems, such as obesity, insulin resistance, and the development of cardiovascular disease (CVD)." | ( Chang, D; Cheng, Y; Su, X, 2021) |
| "Background-Dyslipidemia is one of the prominent risk factors for cardiovascular disease, which is the leading cause of death worldwide." | ( Kang, P; Kim, KY; Shin, HY, 2021) |
| "Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease and a leading cause of death worldwide." | ( Du, YW; Ren, DW; Wang, J; Wang, YX; Wu, SX; Yang, BL; Yang, HM; Yang, YY; Zhang, YY; Zhao, Y; Zhou, HM, 2021) |
| "Dyslipidemia is a common condition that increases the risk of heart diseases and stroke." | ( Akamnonu, I; Nguyen, H; Yang, T, 2021) |
| "Dyslipidemia is a main risk factor of cardiovascular disease in the diabetic patients." | ( Wang, S; Yan, X, 2021) |
| "Dyslipidemia is a significant threat to public health worldwide and the identification of its pathogenic mechanisms, as well as novel lipid-lowering agents, are warranted." | ( Antonie, NI; Cozma, MA; Diaconu, CC; Dobrică, EC; Găman, AM; Găman, MA; Stănescu, AMA, 2021) |
| "Posttransplant dyslipidemia is a common condition in renal transplantation recipients (RTR) and is related to poor cardiac outcomes." | ( Çakır, Ü; Karabulut, U, 2021) |
| "Dyslipidemia is recognized as one of the major risk factors for cardiovascular diseases." | ( Colombo, E; D'Angelo, A; Derosa, G; Fiorenza, AM; Girola, A; Guasti, L; Macias, JJC; Maffioli, P; Maresca, AM; Pasini, GF; Raddino, R; Sanchez, CL; Tandurella, N; Triggiani, M, 2022) |
| "Atherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients." | ( Basoglu, OK; Kayikcioglu, M; Tasbakan, MS, 2021) |
| "Dyslipidemia is commonly linked to skeletal muscle dysfunction, accumulation of intramyocellular lipids, and insulin resistance." | ( Braczko, A; Chlopicki, S; Jablonska, P; Jedrzejewska, A; Krol, O; Kus, F; Mika, A; Przyborowski, K; Sledzinski, T; Slominska, EM; Smolenski, RT; Tomczyk, M, 2021) |
| "Dyslipidemias are lipid metabolism alterations that cause increased levels of serum lipoprotein, cholesterol, and triglycerides." | ( Alves Barros, AS; Barbosa, R; Cesar Matias Pereira, A; de Oliveira Carvalho, H; Faria E Souza, BS; Fernandes, CP; Leticia Elizandra Boettger, M; Lobato Duarte, J; Maciel Ferreira, A; Maciel Ferreira, I; Santos Rodrigues, AP; Tavares Carvalho, JC, 2020) |
| "Dyslipidemia is very prevalent and half of the people with high cholesterol is not aware of having high values." | ( Calvani, R; Ciciarello, F; Cipriani, MC; Landi, F; Liperoti, R; Martone, AM; Marzetti, E; Paglionico, A; Petricca, L; Picca, A; Rocchi, S; Santoro, L, 2022) |
| "Diabetic dyslipidemia is caused by hyperglycemia and excessive mobilization of storage lipids, leading to increasing concentrations of triglycerides and total cholesterol." | ( Ghalichi, F; Ostadrahimi, A; Saghafi-Asl, M, 2022) |
| "Dyslipidemia is common in SCH patients." | ( Mb, V; S, S, 2022) |
| "Dyslipidemia is considered a major risk factor for various cardiovascular diseases." | ( B K, SK; Baral, S; Gyawali, P; Kshetri, R; Pokhrel, A; Regmi, P, 2022) |
| "Hypertension and dyslipidemia are considered reversible risk factors for cardiovascular disease." | ( Li, G; Shi, C; Sun, Y; Zhang, D; Zhang, X, 2022) |
| "Dyslipidemia is one of the most common metabolic disorders." | ( Abd, BA; Hameed, EN; Sharba, ZF; Shareef, RH, 2021) |
| "Dyslipidemia is an important risk factor for hypertension and is strongly associated with an elevated risk of cardiovascular diseases including atherosclerosis and stroke." | ( Chen, SC; Lin, YH; Liu, YH; Su, HM; Wu, DW, 2022) |
| "Dyslipidemia is an established risk factor for cardiovascular disease (CVD), which remains the leading cause of morbidity and mortality in women globally." | ( Minissian, MB; Shufelt, CL; Torbati, T; Torosyan, N; Visrodia, P, 2022) |
| "Dyslipidemia is one of the major public health problems in China." | ( Duan, Q; Hong, N; Huang, Y; Lin, Y; Xie, S; Yang, C; Ye, Z, 2022) |
| "Dyslipidemia is one of the major risk factors for the development of cardiovascular disease (CVD) in patients with type 2 diabetes (T2D)." | ( Basson, AK; Dludla, PV; Mabhida, SE; Mazibuko-Mbeje, SE; Mthembu, SXH; Muller, CJF; Nkambule, BB; Nyambuya, TM; Orlando, P; Silvestri, S; Tiano, L; Ziqubu, K, 2023) |
| "Dyslipidemia is often observed in rheumatic diseases, such as ankylosing spondylitis (AS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), yet it remains to be detected whether rheumatic diseases have a causal effect on dyslipidemia." | ( Cai, Y; Dang, X; Jing, Z; Liang, J; Lv, L; Song, J; Song, Q; Zhang, G; Zhang, J; Zhang, R, 2022) |
| "Dyslipidemia is a risk factor for POAG." | ( Gao, Y; Huang, G; Li, L; Wang, J; Yan, Y, 2022) |
| "Dyslipidemia is a major risk factor for atherosclerosis." | ( Al Alwan, I; AlAqeel, A; AlBuhairan, F; AlDubayee, M; AlFaraidi, H; AlJuraibah, F; AlMuhaidib, S; Babiker, A; Badri, M; Tamimi, W, 2022) |
| "Dyslipidemia is also a strong risk factor for ischaemic stroke and has no relatioship to the other etiologies of stroke." | ( Nussbaumerová, B, 2022) |
| "Patients with dyslipidemia are at increased risk for suicide, especially those with major depressive disorder (MDD)." | ( Cai, Y; Jiang, Y; Liu, C; Lu, Y; Zhang, XY, 2023) |
| "Dyslipidemia is a common disease in the older population and represents a considerable disease burden worldwide." | ( Ge, X; Li, A; Liu, X; Mei, Y; Wei, L; Wu, J; Xu, J; Xu, Q; Yin, G; Zhao, M, 2023) |
| "Dyslipidemia is one of the modifiable risk factors for cardiovascular disease and a leading cause of morbidity and mortality worldwide." | ( Ali, N; Islam, F; Kathak, RR; Samadder, M, 2023) |
| "Dyslipidemia is a potentially modifiable risk factor in patients with chronic kidney disease (CKD)." | ( Bagga, A; Hari, P; Khandelwal, P; Lakshmy, R; Ramesh, PL; Sinha, A, 2023) |
| "Dyslipidemia is closely associated with metabolic syndrome, a known risk factor for colorectal cancer." | ( Jia, G; Long, J; Shu, XO; Wen, W; Yuan, F; Zheng, W, 2023) |
| "IFG and dyslipidemia are highly prevalent among HIV-infected ART-naïve Mexican patients, therefore, screening for glucose and lipids abnormalities always should be considered among ARTn patients." | ( Elizalde-Barrera, CI; Juárez-Mendoza, CV; Maliachi-Díaz, A; Rosado-Arenas, IA; Sandoval-Ocampo, S; Tinoco-Montes, LE, 2023) |
| "Dyslipidemias are linked to hemostatic alterations." | ( Aravena, C; Aravena, D; Echeverría, C; Eltit, F; Gatica, S; Llancalahuen, FM; Prado, Y; Riedel, CA; Simon, F, 2023) |
| "Dyslipidemia is obviously an important risk factor for cardiovascular diseases, which might further lead to disability and death in aged population." | ( Jiang, Y; Li, Q; Li, Y; Song, A; Xu, R; Xu, X, 2023) |
| "Dyslipidemia is a common chronic disease that increases the risk of cardiovascular disease." | ( Hong, G; Jeon, H; Kim, CG; Lee, KJ; Shim, SR; Shin, D; Wu, Y, 2023) |
| "Diabetic dyslipidemia is a crucial link between type-2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular diseases (ASCVD)." | ( Roy, A; Shehnaz, SI; Sivanesan, S; Vijayaraghavan, R, 2023) |
| "Dyslipidemia is a major risk factor for stroke, following hypertension, diabetes, and smoking, and is an important risk factor for the prevention and treatment of coronary artery disease and peripheral vascular disease, including stroke." | ( Chang, Y; Eom, S; Kim, M; Song, TJ, 2023) |
| "Dyslipidemia is the imbalance of various lipids in our body like cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein." | ( Dawadi, BR; Pokharel, K, 2023) |
| "Dyslipidemia is the most common risk factor for cardiovascular disease, causing more than 4 million deaths each year worldwide." | ( Addisu, B; Bekele, S; Cheneke, W; Hirigo, AT; Wube, TB, 2023) |
| "Dyslipidemia is a well-established cardiovascular disease (CVD) risk factor, although its association with mortality is less clear." | ( Myers, J; Vainshelboim, B, 2023) |
| "Dyslipidemia is one of the important contributors to cardiovascular disease and type 2 diabetes." | ( Ali, N; Fariha, KA; Islam, F; Kathak, RR; Taher, A, 2023) |
| "Dyslipidemia is a modifiable risk factor for cardiovascular disease." | ( Jiang, Z; Kizilbash, SJ; Mahajan, R; Zangla, E, 2024) |
| "Dyslipidemia is characterized by elevated levels of total cholesterol and triglycerides in serum, and has become the primary human health killer because of the major risk factors for cardiovascular diseases." | ( Bai, G; Han, Y; Hou, Y; Jiang, M; Lei, W; Liu, W; Lu, Y; Ma, X; Shen, F; Zhang, K; Zhang, T, 2023) |
| "Dyslipidemia is a lifestyle-related (physical inactivity or obesity) disease; therefore, dietary foods that can easily be consumed in daily life is important to prevent dyslipidemia." | ( Kuwabara, N; Nakagawa, S; Sato, S, 2023) |
| "Dyslipidemia is a modifiable major risk factor for coronary heart disease." | ( Berhane, Y; Gobena, T; Motuma, A; Shiferaw, K; Teji Roba, K; Worku, A, 2023) |
| "Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels." | ( Lee, J; Lee, SH, 2023) |
| "The prevalence of dyslipidemia is increased in postmenopausal women due to dysregulation of lipid metabolism and deficiency of estrogen levels." | ( Lei, X; Li, YM; Yu, LL, 2023) |
| "Similarly, dyslipidemia is a common complication in patients with COVID-19, indicating that there may be a pathophysiological interaction between lipid metabolism and SARS-CoV-2." | ( Armonis, C; Fragkou, A; Grigoropoulou, P; Komnianou, K; Kyritsi, E; Tousoulis, D; Toutouzas, K, 2023) |